Risk of second cancers in Waldenström macroglobulinemia

M. Varettoni, A. Tedeschi, L. Arcaini, C. Pascutto, E. Vismara, E. Orlandi, F. Ricci, A. Corso, A. Greco, S. Mangiacavalli, M. Lazzarino, E. Morra

Research output: Contribution to journalArticle

Abstract

Background: An increased incidence of second cancers has been reported in lymphoproliferative disorders. Patients and methods: We assessed the frequency, characteristics and predictive factors of second cancers in 230 patients with Waldenström macroglobulinemia (WM) and compared the incidence of second cancers in WM with that of an age- and sex-matched control population. Results: Twenty-two patients (10%) developed solid cancers and 10 (4%) second hematologic malignancies. In a competing risk model, the cumulative incidence of solid cancers was 12% at 10 years and 17% at 15 years while the incidence of hematologic malignancies was 6% and 8%, respectively. The overall risk of second cancer in WM was 1.69 times higher than expected (P = 0.002). WM patients were at increased risk for diffuse large B-cell lymphoma [standardized incidence ratio (SIR) 9.24, P <0.0001], myelodisplastic syndrome/acute myeloid leukemia (SIR 8.4, P <0.0001), brain cancer (SIR 8.05, P = 0.0004). The risk of a second hematologic malignancy was fourfold higher in patients previously treated, though not reaching statistical significance (P = 0.19). Conclusions: WM patients are at higher risk of second cancers as compared with the general population. The sample size does not allow firm conclusions about the effect of therapy on the development of second cancers.

Original languageEnglish
Pages (from-to)411-415
Number of pages5
JournalAnnals of Oncology
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Waldenstrom Macroglobulinemia
Second Primary Neoplasms
Incidence
Hematologic Neoplasms
Lymphoproliferative Disorders
Lymphoma, Large B-Cell, Diffuse
Acute Myeloid Leukemia
Brain Neoplasms
Sample Size
Population
Neoplasms

Keywords

  • Hematologic malignancies
  • Second cancers
  • Solid tumors
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Risk of second cancers in Waldenström macroglobulinemia. / Varettoni, M.; Tedeschi, A.; Arcaini, L.; Pascutto, C.; Vismara, E.; Orlandi, E.; Ricci, F.; Corso, A.; Greco, A.; Mangiacavalli, S.; Lazzarino, M.; Morra, E.

In: Annals of Oncology, Vol. 23, No. 2, 02.2012, p. 411-415.

Research output: Contribution to journalArticle

Varettoni, M, Tedeschi, A, Arcaini, L, Pascutto, C, Vismara, E, Orlandi, E, Ricci, F, Corso, A, Greco, A, Mangiacavalli, S, Lazzarino, M & Morra, E 2012, 'Risk of second cancers in Waldenström macroglobulinemia', Annals of Oncology, vol. 23, no. 2, pp. 411-415. https://doi.org/10.1093/annonc/mdr119
Varettoni, M. ; Tedeschi, A. ; Arcaini, L. ; Pascutto, C. ; Vismara, E. ; Orlandi, E. ; Ricci, F. ; Corso, A. ; Greco, A. ; Mangiacavalli, S. ; Lazzarino, M. ; Morra, E. / Risk of second cancers in Waldenström macroglobulinemia. In: Annals of Oncology. 2012 ; Vol. 23, No. 2. pp. 411-415.
@article{b86ade8bc7f9410189a5306043e76338,
title = "Risk of second cancers in Waldenstr{\"o}m macroglobulinemia",
abstract = "Background: An increased incidence of second cancers has been reported in lymphoproliferative disorders. Patients and methods: We assessed the frequency, characteristics and predictive factors of second cancers in 230 patients with Waldenstr{\"o}m macroglobulinemia (WM) and compared the incidence of second cancers in WM with that of an age- and sex-matched control population. Results: Twenty-two patients (10{\%}) developed solid cancers and 10 (4{\%}) second hematologic malignancies. In a competing risk model, the cumulative incidence of solid cancers was 12{\%} at 10 years and 17{\%} at 15 years while the incidence of hematologic malignancies was 6{\%} and 8{\%}, respectively. The overall risk of second cancer in WM was 1.69 times higher than expected (P = 0.002). WM patients were at increased risk for diffuse large B-cell lymphoma [standardized incidence ratio (SIR) 9.24, P <0.0001], myelodisplastic syndrome/acute myeloid leukemia (SIR 8.4, P <0.0001), brain cancer (SIR 8.05, P = 0.0004). The risk of a second hematologic malignancy was fourfold higher in patients previously treated, though not reaching statistical significance (P = 0.19). Conclusions: WM patients are at higher risk of second cancers as compared with the general population. The sample size does not allow firm conclusions about the effect of therapy on the development of second cancers.",
keywords = "Hematologic malignancies, Second cancers, Solid tumors, Waldenstr{\"o}m macroglobulinemia",
author = "M. Varettoni and A. Tedeschi and L. Arcaini and C. Pascutto and E. Vismara and E. Orlandi and F. Ricci and A. Corso and A. Greco and S. Mangiacavalli and M. Lazzarino and E. Morra",
year = "2012",
month = "2",
doi = "10.1093/annonc/mdr119",
language = "English",
volume = "23",
pages = "411--415",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Risk of second cancers in Waldenström macroglobulinemia

AU - Varettoni, M.

AU - Tedeschi, A.

AU - Arcaini, L.

AU - Pascutto, C.

AU - Vismara, E.

AU - Orlandi, E.

AU - Ricci, F.

AU - Corso, A.

AU - Greco, A.

AU - Mangiacavalli, S.

AU - Lazzarino, M.

AU - Morra, E.

PY - 2012/2

Y1 - 2012/2

N2 - Background: An increased incidence of second cancers has been reported in lymphoproliferative disorders. Patients and methods: We assessed the frequency, characteristics and predictive factors of second cancers in 230 patients with Waldenström macroglobulinemia (WM) and compared the incidence of second cancers in WM with that of an age- and sex-matched control population. Results: Twenty-two patients (10%) developed solid cancers and 10 (4%) second hematologic malignancies. In a competing risk model, the cumulative incidence of solid cancers was 12% at 10 years and 17% at 15 years while the incidence of hematologic malignancies was 6% and 8%, respectively. The overall risk of second cancer in WM was 1.69 times higher than expected (P = 0.002). WM patients were at increased risk for diffuse large B-cell lymphoma [standardized incidence ratio (SIR) 9.24, P <0.0001], myelodisplastic syndrome/acute myeloid leukemia (SIR 8.4, P <0.0001), brain cancer (SIR 8.05, P = 0.0004). The risk of a second hematologic malignancy was fourfold higher in patients previously treated, though not reaching statistical significance (P = 0.19). Conclusions: WM patients are at higher risk of second cancers as compared with the general population. The sample size does not allow firm conclusions about the effect of therapy on the development of second cancers.

AB - Background: An increased incidence of second cancers has been reported in lymphoproliferative disorders. Patients and methods: We assessed the frequency, characteristics and predictive factors of second cancers in 230 patients with Waldenström macroglobulinemia (WM) and compared the incidence of second cancers in WM with that of an age- and sex-matched control population. Results: Twenty-two patients (10%) developed solid cancers and 10 (4%) second hematologic malignancies. In a competing risk model, the cumulative incidence of solid cancers was 12% at 10 years and 17% at 15 years while the incidence of hematologic malignancies was 6% and 8%, respectively. The overall risk of second cancer in WM was 1.69 times higher than expected (P = 0.002). WM patients were at increased risk for diffuse large B-cell lymphoma [standardized incidence ratio (SIR) 9.24, P <0.0001], myelodisplastic syndrome/acute myeloid leukemia (SIR 8.4, P <0.0001), brain cancer (SIR 8.05, P = 0.0004). The risk of a second hematologic malignancy was fourfold higher in patients previously treated, though not reaching statistical significance (P = 0.19). Conclusions: WM patients are at higher risk of second cancers as compared with the general population. The sample size does not allow firm conclusions about the effect of therapy on the development of second cancers.

KW - Hematologic malignancies

KW - Second cancers

KW - Solid tumors

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=84856362228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856362228&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdr119

DO - 10.1093/annonc/mdr119

M3 - Article

C2 - 21525403

AN - SCOPUS:84856362228

VL - 23

SP - 411

EP - 415

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -